Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.
J Connor WellsAven SidhuKeyue DingMartin SmoragiewiczDaniel Y C HengFrances A ShepherdPeter Michael EllisPenelope A BradburyDerek J JonkerLillian L SiuKaren A GelmonChristos KarapetisJeremy ShapiroLouise NottChristopher J O'CallaghanWendy R ParulekarLesley SeymourJose G MonzonPublished in: The oncologist (2022)
One in 5 patients in phase III clinical trials report using CM. CM was not associated with worse cancer-specific outcomes. However, CM users had more favorable baseline prognostic factors, and likely other confounders that may have contributed to improved outcomes observed in the lung cohort. Physicians should monitor for CM use and potential interactions with clinical trial drugs.
Keyphrases
- phase iii
- clinical trial
- prognostic factors
- open label
- phase ii
- papillary thyroid
- double blind
- end stage renal disease
- squamous cell
- chronic kidney disease
- study protocol
- newly diagnosed
- ejection fraction
- primary care
- squamous cell carcinoma
- patient reported outcomes
- risk assessment
- adipose tissue
- randomized controlled trial
- insulin resistance